HTB homepage • Conference reports • Articles by subject • Subscribe March 2014 Contents Editorial March/April 2014: Volume 15 Number 3/4 Conference reports 21st Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2014, Boston No HIV transmissions with undetectable viral load: interim PARTNER study results show need for longer follow-up PrEP injections every three months may protect against exposure from anal sex ARV pipeline: doravirine, GSK-744 and BMS-068 Viral load rebound rate of 35% using ritonavir-boosted PI monotherapy: results of five-year PIVOT study Dual therapy less effective at high viral load: NEAT 001 study with raltegravir/darunavir/r Atazanavir, raltegravir and darunavir virologically equivalent in naive patients but significant differences for tolerability: results from ACTG 5257 Pharmacokinetic targets for efavirenz might be too high Abacavir link to cardiovascular events in high-risk patients maintained in D:A:D study NNRTI resistance found in 12% of people stopping treatment with undetectable viral load: implications for stock-outs HIV related infections remain the leading cause of maternal deaths in South Africa despite the availability of ART Lower newborn bone mineral content with maternal tenofovir use Paediatric pipeline: CROI 2014 update on new antiretrovirals for children Efavirenz maintenance therapy effective in children exposed to nevirapine prophylaxis Xpert TB test has important advantages but does not reduce morbidity Reports of a second baby possibly cured of HIV: uncertainty remains Updates on SB728-T, a CCR5-targeting gene therapy Treatment access FDA approvals of generic ARVS Paediatric care FDA approves raltegravir for children older than 4 weeks Guidelines UK guidelines for HIV-related cancers (2014): published online Draft BHIVA pregnancy guidelines (2014) online for comment Strong recommendations in WHO 2014 guidelines are often based on lower quality evidence than indicated in GRADE approach Hepatitis coinfection Pharma refuses to ensure access to lifesaving hepatitis C treatment at global meeting New treatments for HCV: strategies for achieving universal access Basic science and immunology The prognostic value of interleukin-6 and D-dimer levels in primary HIV infection HIV reservoir: CD4 T stem cells may facilitate long-term persistence Update published on the first Berlin patient Poor CD4 T cell recovery despite HIV suppression linked to increased morbidity and mortality The relevance of the CD4/CD8 ratio in the ART era First human trial of AAV as a delivery vehicle for HIV neutralising antibodies gets underway On the web Conference resources Online articles PDFs Volume 15 Number 3/4 March/April 2014 PDF HTB homepage • Conference reports • Articles by subject • Subscribe
